IMRN vs INAB

Immuron Limited vs IN8bio, Inc. — Valuation Comparison 2026

IMRN

Biotechnology
Immuron Limited
Quality
1.7
out of 10
Value Trap
Price
$1.21
Last close
Models
7/13
Active
VS

INAB

Biotechnology
IN8bio, Inc.
Quality
3.2
out of 10
Value Trap
36
LOW
Price
$1.80
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType IMRN Fair ValueIMRN Upside INAB Fair ValueINAB Upside
Bayesian DCF Intrinsic $0.32 -73.5% $1.60 -10.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.41 -66.3% $3.60 +99.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMRN vs INAB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMRN vs INAB — Which Stock Is More Undervalued?

INAB scores higher with a 3.2/10 quality rating vs IMRN's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Immuron Limited (IMRN) and IN8bio, Inc. (INAB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMRN currently trades at $1.21 with a QOC of 1.7/10, while INAB trades at $1.80 with a QOC of 3.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).